2015
Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both?
Saifee NH, Krause PJ, Wu Y. Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both? Journal Of Clinical Apheresis 2015, 31: 454-458. PMID: 26481763, DOI: 10.1002/jca.21429.Peer-Reviewed Original ResearchConceptsExchange transfusionHigh-risk populationLife-threatening illnessApparent therapeutic benefitBlood transfusionModerate diseaseClinical presentationAsymptomatic infectionSevere babesiosisSevere diseaseRisk populationsTherapeutic benefitTransfusionMortality rateIntraerythrocytic protozoan parasiteBabesia infectionDiseaseIxodes ticksProtozoan parasiteBabesiosisInfectionGenus BabesiaMost casesPatientsClindamycinBabesiosis
Vannier EG, Diuk-Wasser MA, Mamoun C, Krause PJ. Babesiosis. Infectious Disease Clinics Of North America 2015, 29: 357-370. PMID: 25999229, PMCID: PMC4458703, DOI: 10.1016/j.idc.2015.02.008.Peer-Reviewed Original Research
2002
Babesiosis
Krause PJ. Babesiosis. Medical Clinics Of North America 2002, 86: 361-373. PMID: 11982307, DOI: 10.1016/s0025-7125(03)00092-0.Peer-Reviewed Original ResearchConceptsAge 50 yearsFlulike illnessThin blood smearsHIV infectionHospital admissionExchange transfusionAsplenic individualsImmunosuppressive drugsPolymerase chain reactionSevere casesSpecific diagnosisFatal diseaseBlood smearsProtozoal parasitesGreater riskLyme diseaseSpecific antibodiesChain reactionTransmits Lyme diseaseInfectionDiseaseBabesiosisSame tickNorthern midwestern United StatesMost cases